🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Hosting a research day around wearables and implantables! Fill out form below to note your interest👇

Announcing achira.ai  Achira will usher in the next phase of AI for drug discovery building atomistic foundation models for biomolecular simulation to harness the explosive growth of available computation and the frontiers of physics-based synthetic data

Historic day for builders in bio: We’ve open-sourced Vevo Therapeutics’s #Tahoe100M, largest single-cell atlas ever—by a wide margin—as the inaugural contribution to Arc Institute’s Virtual Cell Atlas, ready for download today. A leap forward for AI models of cells & drug discovery. 🧵

Cool longevity display by Medtronic in Grand Central this morning…how many books would you read if you lived to 150?

A recent article from BioCentury highlights how we are advancing the next era of precision medicine, specifically using AI and RWD to provide more holistic views of patients and their predicted responses to drugs. Read here: biocentury.com/article/655359…

Fascinating report calling out the strategic importance of high quality/accessible biological data for U.S. researchers… excited to see what comes of the “Web of Biological Data” recommendation in Chapter 4

The new Bits in Bio website is officially up and running, check it out here: bitsinbio.org Huge shoutout to Wunderdogs for designing and developing the site. They were thoughtful partners from day one and truly helped us bring the spirit of Bits in Bio online.

Today, we announced that we're building the largest foundation model that's ever been built in oncology, in collaboration with AstraZeneca and Pathos. This project is the culmination of years of work. A foundation model like this has the potential to unlock a myriad of

We're excited to announce Tempus Loop, a new oncology-focused platform for target discovery and validation. Loop is our proprietary approach to novel target identification that integrates real-world patient data (#RWD) with human-derived biological models and CRISPR-screens, all

Bio is Ultimate Big Data Science, and TempusAI is positioning itself to be in the center of it!

Today, we’re announcing a long-term collaboration with Novo Nordisk that represents a step change in how we can expect healthcare access to work in the US. More on the news here: news.hims.com/newsroom/hims-…

looking forward to another Air Street Capital nyc ai happy hour, hosted with @normalcomputing this weds 5/7 ft. friends from databricks, argent, datadog, nomic, yale, cohere, hume, palantir, jp morgan, morgan stanley, jane street, reflection ai, deepmind, semianalysis, patronus ai,

Last year, Compound and USV co-hosted a Research Day on Biohacking. We thought the event was a culmination of our exploration of the field, but it opened our eyes to larger healthcare changes underway, with more company building than expected. We want to continue to

Very excited to announce the first **RNA x Tech Dev Mini-Symposium** in collab with Tri-I RNA Club! Talks from Chris Mason, Ildar Gainetdinov, Xuebing Wu, and s.. Come down to NY Genome Center and hear about the latest in RNA technology development being done in NYC!

The Multiomics Flywheel ARK’s proprietary Multiomics Flywheel blueprint illustrates how AI is powering a self-reinforcing loop that accelerates every aspect of multiomics—from generating biological data, to diagnosing diseases, to developing new drugs and cures.

📣 Proud to share HealthBench, an open-source benchmark from our Health AI team at OpenAI, measuring LLM performance and safety across 5000 realistic health conversations. 🧵 Unlike previous narrow benchmarks, HealthBench enables meaningful open-ended evaluation through 48,562

With Lens, the power of Tempus data is at your fingertips. Quickly define detailed patient cohorts using natural language processing and transform complex criteria into actionable datasets. Explore unstructured clinical data and extract nuanced insights. Discover more at #ASCO25

We’re pleased to share a new, multi-year collaboration with Boehringer Ingelheim that aims to use data and AI to guide biomarker development and patient stratification, develop drug combination hypotheses, support novel target discovery efforts, and more. Learn more:

Tune into Kate Sasser, PhD, on a recent episode of "Behind the Breakthroughs" w/ Jonathan D. Grinstein, PhD. The conversation included a deep dive into Loop—our target discovery platform that integrates #RWD with human-derived biological models and CRISPR-screens, all powered by AI to rapidly